EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Sentinel lymph node biopsy in gynecologic cancers

Priyanka Singh

World Journal of Obstetrics and Gynecology · 2026

DOI: 10.5317/wjog.120261 ↗
AbstractBibliografische Angaben

Abstract

Sentinel lymph node (SLN) biopsy has emerged as a promising, less morbid alternative to complete lymphadenectomy in gynecologic oncology, enabling accurate nodal staging with a reduced surgical burden. Its use has expanded across endometrial, cervical, vulvar, and selected ovarian malignancies. Recent reviews suggest that SLN mapping can lower treatment-related morbidity without compromising oncologic outcomes. However, several challenges persist, including mapping failure, false-negative results, operator learning curves, variability in tracer techniques, and inconsistencies in ultrastaging interpretation. In early-stage cervical cancer, comparative studies demonstrate no significant differences in progression-free or overall survival between SLN biopsy alone and SLN combined with pelvic lymphadenectomy, supporting its use in carefully selected patients. In endometrial cancer, the FIRES trial reported a sensitivity of 97.2% and a negative predictive value of 99.6% with indocyanine green mapping. In response, emerging consensus guidelines aim to standardize SLN assessment to ensure diagnostic accuracy. Nevertheless, global surveys reveal substantial variation in the adoption of SLN strategies across regions and practice settings. While negative sentinel nodes generally obviate the need for further treatment, the detection of micro metastases-particularly in cervical and endometrial cancers-has gained clinical importance, often prompting adjuvant radiotherapy and/or chemotherapy. As precision surgery continues to evolve, this editorial explores whether the current evidence, infrastructure, and multidisciplinary preparedness are sufficient for SLN biopsy to become standard practice, or whether it remains an innovation still awaiting widespread readiness.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →